HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.

The breadth of T cell responses was also higher at Day 168 (EOS) as compared with baseline, although this did not reach statistical significance ( Fig. 2 B).

also in 111,027 other papers